Pharma Pulse 12/12/24: AI Skepticism to Adoption in Pharma Marketing, Biologic Treatments Transforming Severe Asthma Management & more
The latest news for pharma industry insiders.
AI Skepticism to Adoption in the Pharma Marketing Industry
In this part of her Pharmaceutical Executive video interview, Angela Tenuta, President, Full Service Agencies, at EVERSANA INTOUCH, points out how AI is proving its practical value in pharma marketing.
How Biologic Treatments Are Transforming Severe Asthma Management
Earlier this year, researchers of Brigham and Women’s Hospital Harvard Medical School looked at clinical trials to show how six biologics, in particular, improve lung function; cut down on steroid use and lower the risk of asthma attacks.
Lawmakers Eye Bill Forcing Drug Middlemen to Sell Pharmacies
A bipartisan coalition of US lawmakers has drafted legislation that would force prescription drug middlemen to divest pharmacies they own.
SonarMD presented new clinical findings describing the association between anxiety and increased risk for flares and higher disease severity in inflammatory bowel disease (IBD), emphasizing the importance of integrating mental health support within VBC models for IBD management. This poster was shared at the Advances in Inflammatory Bowel Diseases (AIBD) conference in Orlando, FL (Dec. 9-11, 2024).
I hope you've been enjoying our coverage of #trade2024 in Pharmaceutical Commerce Magazine thus far! Day 2 of the conference has been off to a lovely start! Attended multiple sessions back to back. The first was led by Opeyemi Odusami (formerly of Sanofi), who presented on securing the US #supplychain and managing global products. For one, he said, dual sourcing strategies are being implemented in order to balance global efficiency and local reliability, an effort accelerated by the COVID-19 pandemic.
Following Odusami's session was one surrounding the actions needed to mitigate and prevent #drugshortages, presented by Amy Sonderman of US Pharmacopeia. There are various factors correlated with drug shortages - including low prices, manufacturing complexity, production concentration, and quality concerns - and 2023 saw the highest numbers of shortages in the last decade. Stay tuned for coverage of both sessions, which'll be out soon.
I should also tease the plethora of video interviews that are coming down the pike, featuring Kevin O'Meara of EVERSANA; Cheryl Allen and Jon Hamrick of Curatio Scientia Advisors; Dr. Bill Trombetta, PhD., Esq., MBA of Saint Joseph's University; and Lisa Arthurs of Two Labs.
Carpe diem!
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
